Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SIMI VALLEY, California.—The White House has greenlit a plan to design and build a frigate domestically as part of its proposed “Golden Fleet,” Navy Secretary John Phelan announced at the Reagan ...

The Trump administration offered states a deal: pledge to enact White House-favored policies for a chance to win a bigger share of the $50 billion aimed at transforming the nation’s struggling rural ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Abstract: The promise of model-predictive control (MPC) in robotics has led to extensive development of efficient numerical optimal control solvers in line with differential dynamic programming ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The irony is striking: You're running a data center with ...

Chip programming solutions provider Data I/O was recently targeted in a ransomware attack that has caused significant disruption to the company’s operations. Data I/O offers electronic device ...

In a bid to overcome shortcomings in scientific computing, Chinese scientists have unveiled a new approach to sorting data that promises both higher speed and lower energy consumption. The system ...

The credit card processing industry is undergoing a major change since Visa announced the Commercial Enhanced Data Program (CEDP), which went live in the U.S. in April. This new program replaces the ...